What is Epitopix?
Epitopix is a key player in the veterinary vaccine market, dedicated to developing and manufacturing innovative solutions for animal health. The company leverages proprietary technologies, including its patented Siderophore Receptors and Porins (SRP) technology, to create targeted disease prevention strategies. Epitopix specializes in autogenous vaccines, working closely with veterinarians to address specific bacterial and viral pathogens in poultry, bovine, and swine. Their commitment extends to enhancing food animal performance and health globally, serving the veterinary and livestock industries with customized vaccine formulations.
How much funding has Epitopix raised?
Epitopix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Epitopix
PPP
Public-Private Partnership
What's next for Epitopix?
With substantial late-stage funding, Epitopix is poised for accelerated expansion and further technological advancement. The strategic investment is expected to fuel the scaling of its operations, enhance its research and development capabilities, and broaden its market reach. This capital infusion will likely support the commercialization of new vaccine platforms and strengthen its position as a leader in specialized veterinary health solutions, aiming to meet the evolving demands of global animal agriculture.
See full Epitopix company page
